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The Dilated Aorta in Patients
With Congenital Cardiac Defects
Anji T. Yetman, MD, FACC,* Thomas Graham, MD, FACC†
Salt Lake City, Utah; and Nashville, Tennessee
Many patients with congenital cardiac disease are at risk for progressive aortic dilation. The mechanisms under-
lying aortic dilation in this patient cohort are described, and the similarities to the pathophysiologic alterations
seen in Marfan syndrome are highlighted. Indications for treatment are discussed. (J Am Coll Cardiol 2009;53:
461–7) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.035F
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fiver the last decade there has been an accumulating body of
ublished data documenting progressive aortic dilation in
atients with both repaired and unrepaired congenital cardiac
efects (1–5). Several explanations might account for this rise
n disease recognition, including a growing number of patients
ith congenital cardiac defects surviving into adulthood, im-
rovements in cardiac imaging, and perhaps most importantly,
shift in the framework in which we conceptualize ascending
ortic dilation; moving from a paradigm of aortic dilation as
post stenotic dilation” (6) to one of primary aortopathy (7).
Although the natural history of aortic dilation has been
ocumented in certain genetic disorders, namely Marfan syn-
rome (8), the natural history and functional significance of
ortic dilation in patients with congenital heart disease remains
ess well defined. While a number of patients with congenital
ardiac defects will go on to develop progressive aortic dilation
nd the attendant complications of aortic valve insufficiency,
issection, or rupture, the risk of these complications in any
ndividual patient remains unknown. As a result of this
ncertainty, questions regarding the need for, and timing of,
edical and/or surgical therapies have arisen. This review will
utline those patients at risk for progressive dilation of the
horacic aorta and explore the common pathophysiologic
lterations present in an otherwise seemingly disparate patient
roup. The role of therapies for preventing aortic dilation will
e explored.
arfan Syndrome:
he Prototype for All Other Aortopathies?
arfan syndrome occurs as a result of a mutation in the
BN-1 gene encoding for the glycoprotein fibrillin (9).
rom the *Adult Congenital Cardiology Program, Departments of Pediatrics and
edicine, Division of Cardiology, Primary Children’s Medical Center, The Univer-
ity of Utah, Salt Lake City, Utah; and the †Department of Pediatrics, Division of
ardiology, Vanderbilt University, Nashville, Tennessee.g
Manuscript received June 5, 2008; revised manuscript received October 21, 2008,
ccepted October 26, 2008.ibrillin is an integral component of the microfibrils that act
s connectors within the aortic media linking vascular
mooth muscle cells to the surrounding elastic laminae (10).
hese connections allow the vessel to retain elasticity,
xpanding with each cardiac contraction. Fibrillin-1 con-
ains calcium-binding sites that are important in stabilizing
he microfibril against degradation by matrix metallopro-
einases (MMPs) (10). In the face of an altered or deficient
brillin product, these connections are lost, resulting in
mpaired elasticity, vascular smooth muscle cell apoptosis,
nd vulnerability to further destruction of the surrounding
xtracellular matrix by MMPs (10). Aneurysm formation is
he result.
Maladaptive remodeling of the vascular extracellular ma-
rix is not unique to Marfan syndrome. Altered vascular
tructure, irrespective of etiology, may lead to an increased
ropensity for dilation, dissection, or rupture of the aortic
all (11). In 1930, Erdheim (12) coined the term “cystic
edial necrosis” to describe the histologic changes seen in
he aortic media of patients with Marfan syndrome. Refer-
ing to the finding of patchy areas of apoptosis and loss of
he surrounding extracellular matrix, “cystic medial necrosis”
s now known to be common in patients, both adult and
hild, with conotruncal defects (13). Abnormalities of the
ortic media in these conotruncal defects have been found to
e both qualitatively similar and quantitatively identical to
arfan syndrome (13). Whereas an FBN-1 mutation ac-
ounts for the fibrillin deficiency in patients with Marfan
yndrome, fibrillin content is also reduced in both the aorta
nd pulmonary artery of children and adults with a bicuspid
ortic valve (BAV) (10,14). The reduction in fibrillin
ontent is not related to the functional state of the valve
14). In addition, the reduction in fibrillin is not typical of
ortic aneurysms resulting from excessive shear stress, which
ypically result in increased fibrillin (10). The reason for
brillin reduction remains elusive. Mutations in the FBN-1
ene have not been described in association with BAV.
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regulating the processing of
fibrillin-1 into an intact stable
matrix component of the vessel
wall has been postulated (10).
Other gene defects that result in
disruption of the extracellular ma-
trix, thereby initiating a cascade of
vascular smooth muscle cell apo-
ptosis and MMP-mediated vas-
cular damage, have been impli-
cated in the development of both
thoracic aortic and intracranial
aneurysms (15).
The MMPs are a family of proteolytic enzymes that
egrade various components of the extracellular matrix.
ro-MMPs are cleaved into active forms that promote
egradation of matrix proteins. Endogenous tissue inhibi-
ors of metalloproteinases (TIMPs) reduce excessive proteo-
ytic matrix degradation by MMPs. The balance between
MPs and TIMPs is thought to play a critical role in both
ortic and intracerebral aneurysm formation, in both
atients with and without Marfan syndrome (15,16).
The transforming growth factor (TGF) superfamily of
ytokines plays an important role in vascular remodeling.
GF is required for maintenance of vascular health (17).
lterations in signaling activity might enhance matrix
egradation (11). In its inactive state TGF-1 is bound to
atency-associated protein. It has been theorized that fibril-
in plays a key role in sequestering TGF-1, binding it in an
nactive form (18). In this regard, it has been speculated that
he vascular damage observed in Marfan syndrome is
nitiated as a result of a deficient amount of normal fibrillin
apable of binding TGF-1 (18). In support of this theory,
dministration of TGF-1–neutralizing antibodies to fibrillin-
–deficient mice prevents vascular damage (18).
Increased TGF signaling is not limited to the fibrillin-1–
eficient mouse but is present in aneurysms of diverse etiology
nd in diverse locations (11,15,16). Transforming growth
actor -1 might be activated—through cleavage from latency-
ssociated protein—by other substances, including an angio-
ensin II-mediated increase in thrombospondin-1 and reactive
xygen species (17,19). Extracellular matrix disruption from a
ariety of causes might result in the presence of fibrillin
ragments, which themselves have been shown to be potent
timulators of TGF (19). Inhibition of vascular damage—and
hus reduction of free fibrillin fragments—by inhibition of
ngiotensin II or inhibition of MMPs results in a reduction in
GF-1 expression and a reduction in aneurysm formation
17). Conversely, administration of angiotensin II results in
neurysm formation and increased TGF-1 expression (17).
GF-1 Signaling in Cardiac Embryogenesis
lthough the role of TGF in congenital heart disease-
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BAV  bicuspid aortic
valve
MMP  matrix
metalloproteinase
TGF  transforming growth
factor
TIMP  tissue inhibitors of
matrix metalloproteinaseelated aortopathy has yet to be well-defined, perturbations an TGF signaling have been strongly implicated in cardiac
eural crest cell migration and the formation of the cardiac
utflow tracts (20). It has been postulated that these initial
lterations in the TGF signaling pathway lead to the
nderlying conotruncal defect and set the stage for future
neurysmal dilation. Lines of support of an underlying
mbryologic insult responsible for congenital heart disease-
ssociated aortopathy include: 1) patients with BAV have an
ncreased incidence of aneurysms in a variety of neural crest
ell derivatives including ascending aortic aneurysm, cervi-
ocephalic aneurysms, and intracranial aneurysms (21);
) patients with other cardiac defects prone to aortopathy
ave an increased incidence of cervicocephalic and intracra-
ial aneurysms (22); 3) deletion of the TGF-1 receptor
LK5 in mouse neural crest cells leads to conotruncal
bnormalities associated with progressive aortopathy (20);
nd 4) histologic abnormalities of the aorta, in those with
ongenital heart disease-associated aortopathy, are present
s early as the neonatal period (13).
unctional Aortic
mpairment in Patients With Aortopathy
he aorta, irrespective of size, is stiffer and less distensible in
he patient with Marfan syndrome versus a control subject.
mpaired distensibility is present in childhood and becomes
rogressively worse with age. Increased stiffness leads to
ncreased pulse wave reflectance from the periphery, thereby
lacing a greater stress on the ascending aorta. Whether
ortic stiffness merely reflects the degree of histologic
bnormality or is in itself responsible for disease progression
emains unknown. However, it has been shown that aortic
tiffness as measured by magnetic resonance imaging corre-
ates with the rate of aneurysm progression and adverse
utcome in patients with Marfan syndrome (23).
Until recently, the vascular properties of the aorta in
atients with congenital cardiac defects had not been
ell-elucidated. Accumulating evidence suggests a similar
mpairment in aortic distensibility in patients with BAV
24) and tetralogy of Fallot (25). Aortic stiffness is signifi-
antly greater in patients with BAV than in control subjects,
nd this difference remains significant after adjusting for
ortic size and blood pressure. Thus, impaired aortic
tiffness does not result from aortic dilation but rather
xists before dilation and might be instrumental in
urthering aneurysmal development (24). In addition to
redicting further aortic dilation, increased aortic stiff-
ess in patients with repaired tetralogy of Fallot has been
hown to correlate with impaired left ventricular cardiac
utput (25).
ongenital Cardiac Defects
ssociated With Aortopathy
AV. In 1957, McKusick et al. (26) described 4 patients
ith BAV, “cystic medial necrosis” of the ascending aorta,nd associated aortic rupture/dissection. He posited, “The
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February 10, 2009:461–7 Aortopathy and Congenital Heart Diseasessociation of BAV and cystic medial necrosis was more
han coincidence” (27). He likened the observed histologic
lterations to those seen in Marfan syndrome. Numerous
ublications of aortic dissection in association with BAV
ollowed. In 1954, Holman (6) coined the term “post-
tenotic dilation” to refer to the dilated ascending aorta seen
n patients with BAV. This term became part of our daily
omenclature, affecting not only our description of this
natomic alteration but also our conceptualization of the
athologic process. Post-stenotic dilation was not consid-
red a disease entity in itself, and this finding did not invoke
he same concern as an identical-sized aorta in a patient
ith Marfan syndrome. Aortic valve replacement in isola-
ion was commonly performed for aortic valvar dysfunction
espite the presence of a dilated aorta. Left untreated,
reedom from aorta-related complications after isolated
ortic valve replacement in patients with aortic diameters of
4.5 cm was only 43% at 15 years (28).
More recently, BAV has received greater respect among
linicians (3,7,10,24,28). Given a disease incidence of 1% to
% of live births (7), a frequency of concomitant aortic
ilation of 45% to 50% (3,24,29), and an 8% incidence of
issection or rupture in those with dilation (30), global
orbidity and mortality rates associated with BAV aortopa-
hy are staggering. Our understanding of this common
isease entity has only begun to evolve. Current research has
ocused on BAV and thoracic aortic aneurysm as 2 different
anifestations of a single embryologic alteration. Data to
upport this theory include the fact that: 1) patients with
AV have a larger ascending aortic diameter compared with
ge-matched subjects, irrespective of altered valvar hemo-
ynamics; and 2) in patients with a normally functioning
AV, ascending aortic dilation is seen as early as infancy,
nd the rate of ascending aortic growth is greater than that
f matched control subjects (29). Identified risk factors for
ortic dissection in this patient group include: greater aortic
tiffness (24), male sex (7), hypertension (30,31), aortic size
32,33), Turner syndrome (32), family history of aortic
isease (31), and prior coarctation repair (7).
In light of the silent and asymptomatic nature of aortic
ilation and given the high mortality rate associated with
ortic dissection (7,30,32), at least annual follow-up for all
atients with BAV has been recommended (31) to assess for
rogressive aortic enlargement. Because the point of maxi-
al dilation is often more cranial than that seen in Marfan
yndrome (31,34), imaging modalities other than echocar-
iography might be required to fully interrogate the ascend-
ng aorta. Other recommendations include echocardio-
raphic screening of all first-degree family members with a
AV given a 9% to 16% chance of identifying another
ffected family member (7,31).
Historically, aortic replacement was performed when the
orta reached 6.0 cm (33). More refined estimates of annual
isk of aortic dissection/rupture are now available that take
nto account not only aortic diameter but patient size (33).
ortic size relative to body size has been found to be a hreater predictor of aortic complications than absolute aortic
ize (33). For example, a 1.3-m2 person with an aortic
imension of 4 cm has a greater risk of dissection than a
-m2 person with an aortic diameter of 6 cm (33). Plotting
ortic size for body surface area allows for classification of
atients into low, medium, or high risk of developing aortic
omplications, thus, allowing for more timely surgical in-
ervention (33).
In general terms, the recommendations for patients with
AV and ascending aortic aneurysm are the same as those
or patients with Marfan syndrome. The rationale behind
uch recommendations lies in the fact that aortic dissection
ccurs at a similar aortic diameter irrespective of whether
ilation is due to Marfan syndrome or BAV (35). Surgical
ntervention for the aorta is indicated at a diameter of 5.0
m (36). If the aortic valve itself functions normally and is
xpected to have a longevity of 10 years, it should not be
eplaced (36). If the indication for surgical intervention is
alvar dysfunction, concomitant ascending aortic replace-
ent should be performed if the diameter is 4.5 cm or
reater, given the high likelihood of repeat surgical inter-
ention at this diameter (28).
There are accumulating data suggesting that the tensile
trength of the aorta is not to be independent of body size.
ortic dilation has previously been underestimated in pa-
ients with Turner syndrome, due in large part to the
pplication of the standard adult criteria of 4 cm being
sed to define the presence of aortic dilation. Recent work
as demonstrated a cutoff value of 2 cm/m2 for the upper
imits of normal for ascending aortic size in women. In
atients with Turner syndrome this equates to an absolute
alue of 3.4 cm above which aortic dissection has been
eported to occur (32).
It remains a source of controversy as to whether patients
ith BAV should undergo a Ross procedure in the event
hat valve replacement is needed. Progressive aortic dilation,
ut of keeping with somatic growth, is common in children
fter the Ross procedure (37). At 6 years out, freedom from
ortic dilation (z-score 4) is only 3%, freedom from
oderate or greater aortic insufficiency is 60%, and freedom
rom neoaortic reintervention is 88% (37). Risk factors for
rogressive neoaortic dilation include preoperative ascend-
ng aortic diameter, male sex, and post-operative hyperten-
ion (38).
ortic coarctation. The propensity for dilation and dissec-
ion of both the ascending and descending aorta in patients
ith coarctation has long been recognized, with aortic rupture
oted to be the most common cause of death occurring in 19%
f patients before the current surgical era (39). Average life
xpectancy for patients with both coarctation and BAV oper-
ted on until 1981 was 38 years (40).
Patients remain at risk for ascending aortic dissection or
upture, despite timely and successful relief of arch obstruc-
ion. (4). Type of surgical repair, age at initial repair,
resence of residual Doppler pressure gradient, or systemic
ypertension have not been noted to predict late aneurysm
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Aortopathy and Congenital Heart Disease February 10, 2009:461–7ormation (4). Aneurysms may occur in the ascending aorta
ormation, the coarctation repair site, or in the descending
horacic aorta, distal to the repair site (4). “Cystic medial
ecrosis” is visible within the aortic media in the first 24 h
fter birth, again supporting a primary aortopathy (39).
The only predictors of ascending aortic aneurysm in
atients with repaired coarctation include the presence of a
AV and age at follow-up with a risk ratio of 1.4 for every
ecade followed (4). Aneurysm formation at or adjacent to
he coarctation site relates to presence of a BAV, patch
ngioplasty, and older age at repair with a cutoff value of
13.5 years (4).
Because BAV is present in 50% of patients with
oarctation, close surveillance of the ascending aorta as well
s the descending aorta is required. Magnetic resonance or
omputed tomographic angiography is required for ade-
uate imaging in the older patient.
etralogy of Fallot. Single case reports of progressive
scending aortic dilation began appearing in the early 1970s
41). Small case series followed. It was not until the 1990s
hat the frequency of ascending aortic dilation was described
s occurring in 48% of patients (42).
Histologic abnormalities of the aortic media in patients
ith tetralogy of Fallot are similar to that seen in patients
ith Marfan syndrome (17) and have been noted as early as
few days of age (43). Histologic alterations are present
rrespective of the size of the ascending aorta (43). Increased
ortic stiffness has been documented in both children and
dults with repaired tetralogy of Fallot (25).
Risk factors for progressive aortic dilation include the
resence of pulmonary atresia, right aortic arch, history of
n aortopulmonary shunt, male sex, and the presence of a
2q11 deletion (44).
Clinical data on the clinical relevance of these histologic
nd functional abnormalities are accumulating. Whereas
rior to this decade only rare case reports of progressive
ortic dilation in tetralogy of Fallot existed, recent reports
ave quantitated the problem. Niwa et al. (1) noted marked
scending aortic dilation in 15% of adults with repaired
etralogy of Fallot, with the need for surgical intervention in
2%. The ascending aorta should be imaged on a yearly
asis in all patients with tetralogy of Fallot if a progressive
ncrease in aortic diameter, defined as an increase in aortic
-score, has been noted.
The risk of dissection in this patient cohort is being
ncreasingly recognized (1). All dissections have occurred in
atients with aortic diameters 5.5 cm, thus begging the
uestion as to whether ascending aortic replacement should
e undertaken in those patients with an aortic diameter of
55 mm. Measurement of aortic stiffness (25) and aortic
urvature as well as consideration of patient body size (33)
ight enable us to further risk-stratify such patients.
-transposition of the great arteries. It is only of late that
large group of patients with d-TGA are surviving into
dulthood. Although pathologic aortic dilation and dys-
unction have been reported after the Mustard procedure r7), this problem has been largely overshadowed by progres-
ive ventricular dysfunction, arrhythmias, and sudden death.
he incidence of neoaortic dysfunction has been better
uantitated after the arterial switch operation (45), but
iven its relative infancy, the magnitude of this problem
annot be fully appreciated.
Schwartz et al. (46) assessed 335 patients after a median
ollow-up of 5 years and found that at 10 years post-
peration only one-half of patients were free from dilation
f the neoaortic root, defined as a z-score 3. Risk factors
or dilation included previous pulmonary artery banding and
ater date of surgery. Predictors of neoaortic insufficiency
nclude coronary re-implantation technique, discrepancy in
reat vessel size, ventricular septal defect, and rapid devel-
pment of aortic dilation (45). Some patients have gone
n to require neoaortic valvar repair or replacement (45).
ortic dilation, in addition to carrying the risk of aortic
upture, might affect coronary geometry and impair coro-
ary perfusion (47). Because of the relatively recent recog-
ition of this medical problem, clear guidelines for surgical
eintervention are lacking. Progressive aortic insufficiency
nd established size criteria used for BAV might be appli-
able. Aortic geometry might play, as in the patient with
AV, a key role in predisposing to progressive aortic
ilation (48). Patients with acute angulation of the aortic
rch after an arterial switch operation have greater pulse
ave reflection, aortic dilation, and insufficiency (48).
ther lesions. Aortic and pulmonary arterial dissection
ave been reported in association with other cardiac outflow
ract defects, including unrepaired truncus arteriosus (49),
ortopulmonary window (50), and patent ductus arteriosus
51), highlighting the importance of the histologic abnor-
alities identified in the pulmonic trunk if placed under
ystemic pressure.
edical Management
iven the relative frequency and the striking histologic and
unctional similarities in aortic pathology between patients
ith Marfan syndrome and patients with congenital heart
isease-related aortopathy, it seems reasonable to adopt a
edical regimen that has proven beneficial to patients with
arfan syndrome. Unfortunately, there continues to be
reat controversy as to what, if any, medical treatments are
eneficial to the patient with Marfan syndrome. Histori-
ally, -blocker drugs were routinely used to treat patients
ith Marfan syndrome. However, critical review of the
ublished data (52) demonstrates a complete absence of
tudies demonstrating a reduction in risk of aortic dissec-
ion, rupture, or aortic insufficiency in patients treated with
-blockade. This class of drugs is associated with a relatively
igh incidence of side effects (53), and given the paucity of
ata suggesting clinical benefit, their use seems largely
nwarranted. Despite this, -blocker drugs remain the
ainstay of therapy in many centers. This practice largelyeflects the lack of other well-studied medications. Unfor-
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February 10, 2009:461–7 Aortopathy and Congenital Heart Diseaseunately, the routine practice of -blockade in patients with
arfan syndrome is, in itself, what has prevented other
rugs from being evaluated.
Both enhanced TGF-1 and MMP-2 expression and
ther downstream events of angiotensin-II signaling point
o angiotensin-II signaling pathways as targets for preven-
ion of aneurysm formation (17). Data on the use of
ngiotensin-converting enzyme (ACE) inhibitors in hu-
ans with Marfan syndrome have shown short- and
edium-term clinical benefit (53,54). ACE inhibitors block
ormation of angiotensin-II, thereby decreasing TGF-1
ctivity both directly and indirectly through reduction of
eactive oxygen species and thrombospondin, as well as
ecrease MMP activation, restore MMP/TIMP balance,
nd increase the vasodilator bradykinin (Fig. 1).
Angiotensin receptor blocker drugs have been shown to
mprove aortic wall architecture in the Marfan mouse model
n association with a reduction in TGF activity (18).
β
Figure 1 Summary of Proposed Aneurysm-Promoting Mechanism
Active transforming growth factor (TGF) plays a key role in aneurysm formation. In
Marfan syndrome) or in the presence of substances that cleave TGF from latency
gen species). The TGF and ANG II activity leads to matrix metalloproteinase (MM
aortic distensibility. Aortic dilation presenting as aneurysm or increased tortuosity
phosphorylated endothelial nitric oxide synthase; p-SMAD  phosphorylated SMADowever, in vitro studies demonstrate only ACE inhibitor
nd not angiotensin receptor blocker drugs to be effective in
reventing histologic abnormalities and normalizing TGF
ctivity (55,56).
Doxycycline has been demonstrated to be an effective
nhibitor of MMPs. It has been shown to affect aneurysm
rogression in adults with abdominal aortic aneurysms and
ecently has been shown to have a beneficial role in reduction
n aortic MMP levels in Marfan animal models (57).
ummary
ver the last decade there has been exponential growth in
ocumentation of progressive aortic pathology in patients
ith congenital cardiac disease. As this cohort of patients
ontinues to survive into adulthood, the magnitude of this
roblem will be better clarified. With improved understand-
ng of the underlying pathophysiology, we are now better
β
d Sites of Medical Therapies
ed active TGF occurs in the setting of fibrillin deficiency (bicuspid aortic valve,
iated protein (angiotensin II [ANG II]-dependent thrombospodin and reactive oxy-
iated alterations in vascular endothelium and aortic media, resulting in impaired
. At a critical relative aortic diameter, dissection/rupture occurs. p-eNOS 
in; TIMP  tissue inhibitors of matrix metalloproteinase.s an
creas
-assoc
P)-med
follows
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Aortopathy and Congenital Heart Disease February 10, 2009:461–7quipped to study potentially effective medical therapies in
hese patients. However, despite this realization, there
emains a paucity of data assessing the use of any medical
herapy in this patient cohort. The many histological and
unctional similarities between these patients and those with
arfan syndrome behoove us to study, in the former group
f patients, the impact of medical treatments found bene-
cial in the latter. Multicenter trials of medical therapies to
revent progressive aortic pathology in patients with congenital
eart disease-related aortopathy are greatly needed.
eprint requests and correspondence: Dr. Anji T. Yetman,
rofessor of Pediatrics, Adjunct Professor, Medicine, Director,
arfan Cardiology Program, Director, Adult Congenital Cardi-
logy Program, University of Utah, Primary Children’s Medical
enter, 100 N. Mario Capecchi Drive, Salt Lake City, Utah,
4108. E-mail: Angela.Yetman@imail.org.
EFERENCES
1. Niwa K, Siu SC, Webb GD, Gatzoulis MA. Progressive aortic root
dilatation in adults later after repair of tetralogy of Fallot. Circulation
2002;106:1374–8.
2. McMahon CJ, Ravekes WJ, Smith EO, et al. Risk factors for
neo-aortic root enlargement and aortic regurgitation following arterial
switch operation. Pediatr Cardiol 2004;25:329–35.
3. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid
aortic valves. JAMA 2008;300:1317–25.
4. Oliver JM, Gallego P, Gonzalez A, Aroca A, Bret M, Mesa JM. Risk
factors for aortic complications in adults with coarctation. J Am Coll
Cardiol 2004;44:1641–7.
5. Ono M, Goerler H, Boethig D, Westhorr-Bleck M, Hartung D,
Breymann T. Valve-sparing operation for aortic root aneurysm late
after Mustard procedure. Ann Thorac Surg 2007;83:2224–6.
6. Holman E. The obscure physiology of poststenotic dilatation; its
relation to the development of aneurysms. J Thorac Surg 1954;28:
109–33.
7. Friedman T, Mani A, Elefteriades JA. Bicuspid aortic valve: clinical
approach and scientific review of a common clinical entity. Expert Rev
Cardiovasc Ther 2008;6:235–48.
8. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan
syndrome. Am J Cardiol 1995;75:157–60.
9. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by
a recurrent de novo missense mutation in the fibrillin gene. Nature
1991;352:337–9.
0. Fedak PW, de Sa MP, Verma S, et al. Vascular matrix remodeling in
patients with bicuspid aortic valve malformations: implications for
aortic dilation. J Thorac Cardiovas Surg 2003;126:797–806.
1. Jones JA, Barbour JR, Stroud RE, et al. Altered transforming growth
factor-beta signaling in a murine model of thoracic aortic aneurysm. J
Vasc Res 2008;457–68.
2. Erdheim J. Medionecrosis aortae idiopathica cystic. Virchows Arch
Pathol Anat 1930;276:187–229.
3. Niwa K, Perloff JK, Bhuta SM, et al. Structural abnormalities of great
arterial walls in congenital heart disease. Circulation 2001;103:393–413.
4. Huang P, Wang HW, Li Y, et al. Expression of fibrillin-1 in
congenital bicuspid aortic valves. Zhonghua Yi Xue Za Zhi 2007;87:
1549–52.
5. Ruigrok YM, Rinkel GJ, van‘t Slot R, Wolfs M, Tang S, Wijmenga C.
Evidence in favor of the contribution of genes involved in the maintenance
of the extracellular matrix of the arterial wall to the development of
intracranial aneurysms. Hum Mol Genet 2006;15:3361–8.
6. Ikonomidis D, Jones JA, Barbour JR, et al. Expression of matrix
metalloproteinases and endogenous inhibitors within ascending aortic
aneurysms of patients with Marfan syndrome. Circulation 2006;114:
I365–70.7. Gordon KJ, Blobe GC. Role of transforming growth factor- super-
family signaling pathways in human disease. Biochimica et Biophysica
Acta 2008;1782:197–228.
8. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist,
prevents aortic aneurysm in a mouse model of Marfan syndrome.
Science 2006;312:117–21.
9. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth A.
Fibrillin-1 regulates the bioavailability of TGFb-1. J Cell Biol 2007;
176:355–67.
0. Wang J, Nagy A, Larsson J, et al. Defective ALK5 signaling in the
neural crest leads to increased postmigratory neural crest apoptosis and
severe outflow tract defects. BMC Dev Biol 2006;6:51–60.
1. Schievink WI, Mokri B. Familial aorto-cervicocephalic arterial dissec-
tions and congenitally bicuspid aortic valve. Stroke 1995;26:1935–40.
2. Schievink WI, Mokri B, Piepgras DG, Gittenberger-de-Groot AC.
Intracranial aneurysms and cervicocephalic arterial dissections associ-
ated with congenital heart disease. Neurosurgery 1996;39:685–9.
3. Nollen GJ, Groenink M, Tijssen JG, et al. Aortic stiffness and
diameter predict progressive aortic dilatation in patients with Marfan
syndrome. Eur Heart J 2004;25:1146–52.
4. Nistri S, Grande-Allen J, Noale et al. Aortic elasticity and size in
bicuspid aortic valve syndrome. Eur Heart J 2008;29:472–9.
5. Senzaki H, Iwamoto Y, Ishido H et al. Arterial haemodynamics in
patients after repair of tetralogy of Fallot: influence on left ventricular
after load and aortic dilation. Heart 2008;94:70–4.
6. McKusick VA, Logue RB, Bahnson HT. Association of valvular
disease and cystic medial necrosis of the ascending aorta; report of four
instances. Circulation 1957;16:188–94.
7. Mckusick VA. Association of congenital bicuspid aortic valve and
Erdheim’s cystic medial necrosis. Lancet 1972;1:1026–7.
8. Borger MA, Preston M, Ivanov J, et al. Should the ascending aorta be
replaced more frequently in patients with bicuspid aortic valve disease?
J Thorac Cardiovasc Surg 2004;128:677–83.
9. Beroukhim RS, Kruzick TL, Taylor AL, Gao D, Yetman AT.
Progression of aortic dilation in children with a functionally normal
bicuspid aortic valve. Am J Cardiol 2006;98:828–30.
0. Davies RR, Kaple RK, Mandapati D, et al. Natural history of
ascending aortic aneurysm in the setting of an unreplaced bicuspid
aortic valve. Ann Thorac Surg 2006;83:1338–44.
1. Boyer JK, Gutierrez F, Braverman AC. Approach to the dilated aortic
root. Curr Opinion Cardiol 2004;19:563–9.
2. Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and
dissection in Turner syndrome. Circulation 2007;116:1663–70.
3. Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative
aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac
Surg 2006;81:169–77.
4. Beroukhim RS, Roosevelt G, Yetman AT. Comparison of the pattern
of aortic dilation in children with the Marfan‘s syndrome versus
children with a bicuspid aortic valve. Am J Cardiol 2006;98:1094–5.
5. Januzzi JL, Isselbacher EM, Fattori R, et al. Characterizing the young
patient with aortic dissection: results from the international registry of
aortic dissection (IRAD). J Am Coll Cardiol 2004;43:665–9.
6. Bonow RO, Carabello B, Chatterjee K, et al. ACC/AHA 2006
guidelines for the management of patients with valvular heart disease:
a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee
to Develop Guidelines for the Management of Patients With Valvular
Heart Disease). J Am Coll Cardiol 2006;48:e1–148.
7. Pasquali SK, Shera D, Wernovsky G, et al. Midterm outcomes and
predictors of reintervention after the Ross procedure in infants,
children, and young adults. J Thorac Cardiovasc Surg 2007;133:893–9.
8. Brown JW, Ruzmetov M, Rodefeld MD, Mahomed Y, Turrentine
MW. Incidence of and risk factors for pulmonary autograft dilation
after Ross aortic valve replacement. Ann Thorac Surg 2007;83:1781–7.
9. Vogt M, Kuhn A, Baumgartner D, et al. Impaired elastic properties of
the ascending aorta in newborns before and early after successful
coarctation repair: proof of a systemic vascular disease of the prest-
enotic arteries? Circulation 2005;111:3269–73.
0. Cohen M, Fuster V, Steele PM, et al. Coarctation of the aorta.
Long-term follow-up and prediction of outcome after surgical correc-
tion. Circulation 1989;80:840–5.
1. Peters RM. Total repair of tetralogy of Fallot and replacement of aortic
valve with Starr-Edwards prosthesis. Case report. J Thorac Cardiovasc
Surg 1971;61:599–601.
44
4
4
4
4
4
4
5
5
5
5
5
5
5
5
467JACC Vol. 53, No. 6, 2009 Yetman and Graham
February 10, 2009:461–7 Aortopathy and Congenital Heart Disease2. Jonsson H, Ivert T, Brodin LA. Echocardiographic findings in 83
patients 13–26 years after intracardiac repair of tetralogy of Fallot. Eur
Heart J 1995;69:1255–63.
3. Tan JL, Davlouros PA, McCarthy KP, Gatzoulis MA, Ho SY.
Intrinsic histologic abnormalities of aortic root and ascending aorta in
tetralogy of Fallot 2005;112:961–8.
4. Niwa K. Aortic root dilatation in tetralogy of Fallot long-term after
repair-histology of the aorta in tetralogy of Fallot: evidence of intrinsic
aortopathy. Int J Cardiol 103:117–9.
5. Cohen MS, Wernovsky G. Is the arterial switch operation as good
over the long term as we thought it would be? Cardiol Young
2006;16:117–24.
6. Schwartz ML, Gauvreau K, del Nido P, Mayer JE, Colan SD.
Long-term predictors of aortic root dilation and aortic regurgitation
after arterial switch operation. Circulation 2004;110:128–32.
7. Mcmahon CJ, Nihill MR, Denfield S. Neoartic root dilation associ-
ated with left coronary stenosis following arterial switch procedure.
Pediatr Cardiol 2003;24:43–6.
8. Agnoletti G, Ou P, Celermajer DS, et al. Acute angulation of the
aortic arch predisposes a patient to ascending aortic dilation and aortic
regurgitation late after the arterial switch operation for transposition of
the great arteries. J Thorac Cardiol Surg 2008;135:568–72.
9. Gutierrez PS, Binotto MA, Aiello VD, Mansur AJ. Chest pain in an
adult with truncus arteriosus communis. Am J Cardiol 2004;93:272.
0. Le Bret E, Lupoglazoff JM, Bachet, et al. Pulmonary artery dissection
and rupture associated with an aortopulmonary window. Ann Thorac
Surg 2004;78:e67–8. K1. Khush KK, Randhawa R, Israel E. A full house: complications from an
uncorrected patent ductus arteriosus Curr Cardiol Rep 2005;7:310–3.
2. Gersony DR, McClaughlin MA, Jin Z, Gersony WM. The effect of
beta-blocker therapy on clinical outcome in patients with Marfan‘s
syndrome: a meta-analysis. Int J Cardiol 2007;114:303–8.
3. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril
versus propranolol or atenolol for prevention of aortic dilation in
patients with the Marfan syndrome. Am J Cardiol 2005;95:1125–7.
4. Ahimastos AA, Aggarwal A, D’Orsa KM, et al. Effect of perindopril
on large artery stiffness and aortic root diameter in patients with
Marfan syndrome: a randomized controlled trial. JAMA 2007;298:
1539–47.
5. Redondo S, Ruiz E, Padilla E, Gordillo-Moscoso A, Tejerina T. Role
of TGF-1 in vascular smooth muscle cell apoptosis induced by
angiotensin II. Eur J Pharm 2007;556:36–44.
6. Nagashima H, Uto K, Sakomura Y, et al. An angiotensin-converting
enzyme inhibitor, not an angiotensin II type-1 receptor blocker,
prevents beta-aminopropionitrile monofumarate-induced aortic dis-
section in rats. J Vasc Surg 2002;36:818–23.
7. Chung AWY, Yang HHC, Radomski MW, van Breemen C. Long
term doxycycline is more effective than atenolol to prevent thoracic
aortic aneurysm in Marfan syndrome through the inhibition of matrix
metalloproteinase-2 and -9. Circulation Res 2008;102:1–13.ey Words: aneurysm y aorta y dissection.
